Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized single-blind study of imetelstat dose levels in relapsed/refractory myelofibrosis after JAK inhibitor treatment
2015-000946-41Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Apr 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of imetelstat in myelofibrosis (MF) (2 arms), sponsored by Geron Corporation. Primary endpoint: Spleen response rate at Week 24. Started Apr 2015; status: completed.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2015-000946-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000946-41.